follow url Update 1 Mid-day Trading -June 29 Bulls Back in Charge on EU Bank Bailout The market has forgotten about Obamacare and reverted to the number one market issue-Euro debt resolution. Here is a healthcare sector update from today’s trading and our take: Biotechnology: Stocks have resumed their run to all time highs and even mid-caps […]
here Guide to Biotech Investing (Published in Investor Uprising in May 2011) This article is one year old but still relevant! Introduction: Balancing Portfolios With Biotech Rod Raynovich 5/27/2011 Recent breakthroughs with new drugs and devices have eclipsed many of the concerns of healthcare reform. In addition, the pace of innovation is accelerating. These factors are […]
http://larryhefner.com/pharmacy/ BioBuzz Rolls On After a bad day on NASDAQ yesterday with some profit taking in biotech there is a lot of green screen today. The sector is up 1% today and we are near all time highs like the XBI ($86.92). But to many investors, biotechnology is relatively unknown or still perceived as a speculative […]
Sell-off gets worse with S&P down 2%. Moody’s downgrade of banks expected by end of day. Bear market for commodities? ———– We have been at BIO 2012 in Boston over the past week and will provide interesting trends and data from the Meeting by Monday. Global Slowdown Fears: Market off 1.5% at mid-day with the […]
Here are some other good ASCO News sources from MedAdNews: PharmAviary provides a round up of the industry tweets of the week. Chris Truelove, editor in chief of Med Ad News and R&D Directions, scours the healthcare blogosphere to bring you a digestible summary of the big trends and issues that have everyone talking. Updates from #ASCO, and back […]
A Biopharma Stock We Missed-Pharmacyclics (PCYC $38.21) up 9.89% today It is unbelievable that we missed the huge move in PCYC up 157% YTD with a one year range of 7.63 to 38.56. The market cap is $2.63B. The Company has a robust pipeline of products led by Ibrutinib, a Bruton tyrosine kinase (BTK) inhibitor […]
Antibody Drug Conjugates Make Progress for Cancer Therapy- Immunogen and Seattle Genetics Many of our focus stocks were up today helped by a late day rally that brought the NASDAQ up 0.46% at the close. Major biotechnology ETF’s (IBB,XBI) also recovered with some green by the end of the day.The Rayno Life Science Portfolio was […]
Jobs Number Spooks Traders-Dow Erases Gains for the Year Large cap biotechnology and MO growth stocks are taking a big hit today as hedgies take profits. Many of these stocks are still up YTD but profits are quickly eroding. Stocks to watch in technology, retail and biotechnology are :Intuitive Surgical ISRG ($507) down 3%,Lululemon LULU ($70) down 3.5%, […]
PO Box 3701
Manhattan Beach CA 90266
(310) 871-1231
rod@rayno.com
Rod Raynovich is the founder of Raygent Associates, a management consulting firm providing business development and strategic marketing services in the life science and medical device area. He publishes his thoughts and analysis on the biotech industry at www.raygent.com.